Janux Therapeutics JANX Depreciation
Depreciation at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Janux Therapeutics's depreciation?
- Janux Therapeutics (JANX) reported depreciation of $469K in Q1 2026.
- How has Janux Therapeutics's depreciation changed year-over-year?
- Janux Therapeutics's depreciation decreased by 9.6% year-over-year, from $519K to $469K.
- What is the long-term trend for Janux Therapeutics's depreciation?
- Over 4 years (2021 to 2025), Janux Therapeutics's depreciation has grown at a 105.9% compound annual growth rate (CAGR), from $113K to $2.03M.